Eli Lilly and Company (NYSE: LLY) Soars on Strong Q1 Earnings and GLP-1 Drug Demand

Font: Financial Modeling Prep  • May 01, 2026

• Eli Lilly and Company (NYSE: LLY) reported a robust first quarter 2026, showcasing a 56% year-over-year revenue increase to $19.8 billion and an adjusted EPS of $8.55.
• This impressive financial performance is largely fueled by surging global demand for its GLP-1 drugs, Mounjaro and Zepbound, which drove a 65% increase in sales volume and solidified its nearly 60% market share in this critical segment.
• Reflecting strong confidence in its future, the company received an "Overweight" rating and a raised price target from Morgan Stanley (NYSE: MS), alongside significantly increased 2026 revenue and EPS guidance.

Eli Lilly is a global pharmaceutical corporation that discovers, develops, and sells a wide range of medical products. The company is a major player in the market for diabetes and weight-loss treatments. In this space, it faces significant competition from other pharmaceutical giants, most notably Novo Nordisk (NYSE: NVO).

On May 1, 2026, the investment firm Morgan Stanley reiterated its "Overweight" rating for Eli Lilly. An "Overweight" rating means the firm believes the pharmaceutical stock will perform better than the average stock in its sector. Morgan Stanley also raised its price target to $1,344 from $1,327, while the stock was trading at $961.72. This positive investment outlook underscores confidence in Eli Lilly's market position.

This optimistic rating aligns with Eli Lilly's strong first-quarter 2026 performance. The company reported a 56% year-over-year revenue increase, reaching $19.8 billion. It also posted an adjusted earnings per share (EPS) of $8.55. EPS is a key profitability metric, showing how much profit is earned for each outstanding share of stock.

The impressive Q1 earnings report results are driven by surging global demand for its GLP-1 drugs, Mounjaro and Zepbound, which caused a 65% increase in sales volume. As highlighted by Seeking Alpha, Eli Lilly's market share in this diabetes drug market category has stabilized at nearly 60%, maintaining a strong position and market leadership against its primary competitor.

Reflecting this strong performance and positive financial projections, Eli Lilly raised its financial guidance for the full 2026 fiscal year. The company now projects revenues between $82 billion and $85 billion. It also updated its expected earnings per share to a range of $35.50 to $37.00, signaling confidence in its future growth trajectory.